Abstract：Objective To investigate the effect and safety of Amlotinib on lung function in patients with non-small cell lung cancer.Methods A total of 48 patients with non-small cell lung cancer treated in the Jiujiang Third People′s Hospital from December 2018 to December 2019 were selected as the research objects,and divided into the observation group(24 cases)and the control group(24 cases)by random number table method.The control group was treated with Paclitaxel Albumin combined with Cisplatin chemotherapy,and the observation group was treated with Amrotinib on the basis of control group.The therapeutic effect,lung function and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.67%,which was higher than that of the control group(75.07%),and the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences in forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC between the two groups(P＞0.05).After treatment,the levels of FVC,FEV1 and FEV1/FVC in the two groups were higher than before,and the levels of FVC,FEV1 and FEV1/FVC in the observation group were higher than those in the control group,with statistical significances(P＜0.05).The total incidence of adverse reactions in the observation group was 9.10%,which was lower than that in the control group(25.00%),and the difference was statistically significant(P＜0.05).Conclusion Anlotinib in the treatment of non-small cell carcinoma can effectively improve the lung function of patients,control tumor progression,and promote the recovery of the disease,with high safety.
京公网安备 11010502046607号